Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY2A | P04746 | 9/20 | 0.87 |
| ▸ | MGAM | O43451 | 6/20 | 0.87 |
| ▸ | SI | P14410 | 5/20 | 0.87 |
| ▸ | GAA | P10253 | 4/20 | 0.87 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.87 |
| ▸ | CNR1 | P21554 | 1/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.87 |
| ▸ | PDE4A | P27815 | 1/20 | 0.87 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.87 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | GLA | P06280 | 1/20 | 0.87 |
| ▸ | TREH | O43280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935033 | 1.00 | AMY2A (0.87) | AMY2AMGAMSIGAAAMY1A | |
| SCHEMBL24012238 | 0.97 | AMY2A (0.89) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL28219610 | 0.96 | AMY2A (0.94) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL8798558 | 0.96 | AMY2A (0.94) | AMY2AMGAMSIGAAAMY1A | |
| SCHEMBL5161028 | 0.95 | AMY2A (0.88) | AMY2AMGAMSIGAAAMY1A | |
| SCHEMBL29775913 | 0.95 | AMY2A (0.88) | AMY2AMGAMSIGAAAMY1A | |
| SCHEMBL12665813 | 0.95 | AMY2A (0.88) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL22651301 | 0.93 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL4068725 | 0.93 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL22252576 | 0.93 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| EP-3911648-B1 | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20110105420-A1 | AMINOSUGAR COMPOUND AND PROCESS FOR PRODUCTION THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7271158-B2 | Treatment of rumen acidosis with α-amylase inhibitors | PFIZER INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271158-B2 | Treatment of rumen acidosis with α-amylase inhibitors | PFIZER INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1745790-A2 | Treatment of rumen acidosis with alpha-amylase inhibitors | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| US-20050233983-A1 | Treatment of rumen acidosis with alpha-amylase inhibitors | BANKS BERNARD J | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | AMY2A 446/4885MGAM 1753/4885SI 222/4885 |
| US-20110105420-A1 | AMINOSUGAR COMPOUND AND PROCESS FOR PRODUCTION THEREOF | AMY2A, AMY1A, SI | AMY2A 1/4885MGAM 5/4885SI 3/4885 |
| US-20050233983-A1 | Treatment of rumen acidosis with alpha-amylase inhibitors | SI, GANAB, AMY1A | AMY2A 13/4885MGAM 7/4885SI 1/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | AMY2A 778/4885MGAM 1519/4885SI 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.